Literature DB >> 10931187

Echistatin inhibits pp125FAK autophosphorylation, paxillin phosphorylation and pp125FAK-paxillin interaction in fibronectin-adherent melanoma cells.

R Della Morte1, C Squillacioti, C Garbi, P Derkinderen, M A Belisario, J A Girault, P Di Natale, L Nitsch, N Staiano.   

Abstract

Echistatin, a snake-venom RGD-containing protein, was previously shown to disrupt cell-matrix adhesion by a mechanism that involves the reduction of pp125FAK tyrosine phosphorylation levels. The aim of this study was to establish the sequence of events downstream pp125FAK dephosphorylation that could be responsible for echistatin-induced disassembly of actin cytoskeleton and focal adhesions in fibronectin-adherent B16-BL6 melanoma cells. The results obtained show that echistatin induces a decrease of both autophosphorylation and kinase activity of pp125FAK. One hour of cell exposure to echistatin caused a 39% decrease of pp125FAK Tyr397 phosphorylation and a 31% reduction of pp125FAK autophosphorylation activity as measured by immune-complex kinase assay. Furthermore, 1 h of cell treatment by echistatin produced a 63% decrease of paxillin phosphorylation, as well as a reduction in the amount of paxillin bound to pp125FAK. Immunofluorescence analysis of echistatin treated cells showed the concomitant disappearance of both paxillin and pp125FAK from focal adhesions. The reduction of paxillin phosphorylation may represent a critical step in the pathway by which disintegrins exert their biological activity, including the inhibition of experimental metastasis in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10931187     DOI: 10.1046/j.1432-1327.2000.01561.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  9 in total

1.  Biochemical analysis of the molecular mechanism of action of natural integrin inhibitors.

Authors:  A Scibelli; S Tafuri; E Alimenti; M A Belisario; R Della Morte; N Staiano
Journal:  Vet Res Commun       Date:  2003-09       Impact factor: 2.459

2.  Effect of the disintegrin eristostatin on melanoma-natural killer cell interactions.

Authors:  Stefan Hailey; Elizabeth Adams; Ryan Penn; Alice Wong; Mary Ann McLane
Journal:  Toxicon       Date:  2012-11-09       Impact factor: 3.033

3.  Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma.

Authors:  Hai-Gang Li; De-Rong Xie; Xi-Ming Shen; Hong-Hao Li; Hong Zeng; Yun-Jie Zeng
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

Review 4.  Biological Effects of Animal Venoms on the Human Immune System.

Authors:  Zharick Avalo; María Claudia Barrera; Manuela Agudelo-Delgado; Gabriel J Tobón; Carlos A Cañas
Journal:  Toxins (Basel)       Date:  2022-05-16       Impact factor: 5.075

5.  The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner.

Authors:  S Sean Houshmandi; Ryan J Emnett; Marco Giovannini; David H Gutmann
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

6.  Serum from rabbit orally administered cobra venom inhibits growth of implanted hepatocellular carcinoma cells in mice.

Authors:  Peng Sun; Xian-Da Ren; Hai-Wei Zhang; Xiao-Hong Li; Shao-Hui Cai; Kai-He Ye; Xiao-Kun Li
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

7.  Antiproliferative effect of the jararhagin toxin on B16F10 murine melanoma.

Authors:  Durvanei Augusto Maria; Manuela Garcia Laveli da Silva; Mario Cesar Correia Junior; Itamar Romano Garcia Ruiz
Journal:  BMC Complement Altern Med       Date:  2014-11-18       Impact factor: 3.659

Review 8.  Biomedical applications of snake venom: from basic science to autoimmunity and rheumatology.

Authors:  Carlos A Cañas; Santiago Castaño-Valencia; Fernando Castro-Herrera; Felipe Cañas; Gabriel J Tobón
Journal:  J Transl Autoimmun       Date:  2020-12-14

9.  The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.

Authors:  Xinjie Lu; Dong Lu; Mike Scully; Vijay Kakkar
Journal:  Perspect Medicin Chem       Date:  2008-04-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.